Tolerance times (in minutes) for each subject and statistical analysis within groups for team D
| Subject | Precompetition training | Competition | Postcompetition | ||
|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 (placebo plus naloxone) | Week 5 (control) | |
| 1 | 18.5 | 28 | 29 | 19 | 17 |
| 2 | 11 | 22 | 20 | 12 | 11 |
| 3 | 14 | 23.5 | 21.5 | 15 | 10.5 |
| 4 | 17.5 | 27.5 | 27 | 17 | 16 |
| 5 | 10 | 19 | 18.5 | 12 | 11 |
| 6 | 12.5 | 21 | 20 | 14 | 12 |
| 7 | 16.5 | 27 | 28.5 | 18 | 15.5 |
| 8 | 19 | 25 | 26 | 19.5 | 18 |
| 9 | 11.5 | 18 | 18 | 12 | 11 |
| 10 | 15 | 22.5 | 21.5 | 16 | 14 |
| Mean ± SD | 14.5 ± 3.2 | 23.3 ± 3.5 | 23 ± 4.2 | 15.4 ± 2.9 | 13.6 ± 2.8 |
Repeated-measures ANOVA across the 5 weeks: F(4,36)=173.045; p < 0.001. Student–Newman–Keuls: week 3 versus week 1, q(36)= 23.255, p < 0.001; week 2 versus week 4, q(36)= 21.742, p < 0.001; week 3 versus week 4, q(36)= 20.779, p < 0.001; week 2 versus week 5, q(36)= 26.833, p < 0.001; week 3 versus week 5, q(36)= 25.870, p < 0.001; week 4 versus week 5, q(36)= 5.091, p < 0.01; week 2 versus week 1, q(36)= 24.219; p < 0.001. The other comparisons are not significant.